KISQALI® (Ribociclib)

The FDA on March 13, 2017 approved KISQALI®, a cyclin-dependent kinase 4/6 inhibitor, in combination with an Aromatase Inhibitor, as initial endocrine-based therapy for the treatment of postmenopausal women with Hormone Receptor (HR)-positive, Human Epidermal Growth Factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. KISQALI®is a product of Novartis Pharmaceuticals Corp